Physicians' Academy for Cardiovascular Education

First European experience with human MTP-inhibitor in HoFH

Dr. Jeanine Roeters van Lennep

10' education - Oct. 24, 2014

Jeanine Roeters van Lennep, MD PhD (Erasmus MC, Rotterdam, The Netherlands) discusses management of homozygous familial hypercholesterolaemia (HoFH). Recently a position paper was published that discussed causes, diagnosis and treatment options of this difficult to treat condition. Dr. Roeters van Lennep focuses on treatment with the first human MTP-inhibitor, lomitapide. Although it is not reimbursed yet in The Netherlands, the Erasmus Medical Center in Rotterdam has started treating the first patients with lomitapide on a named-patient basis. Roeters van Lennep shares the first experiences in these patients.
 

After having watched this 10’ education you will know more about:

  • the mechanism of action of an MTP-inhibitor
  • how patients should be educated, guided and tested prior to treatment with lomitapide
  • how the first patients with HoFH (various age categories, genotypes and sexes) respond to treatment with lomitapide.

Start video

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: